Literature DB >> 9854686

Effect of finasteride in idiopathic hirsutism.

E Faloia1, S Filipponi, V Mancini, S Di Marco, F Mantero.   

Abstract

Increased 5 alpha-reductase activity has been found in hair follicles of hirsute women, suggesting a pathogenetic role. The aim of the present study was to evaluate the effect of finasteride in the treatment of idiopathic hirsutism. Twenty-seven women with idiopathic hirsutism, aged 16-35 years, were treated for 6 months with finasteride, 5 mg once daily. Fourteen patients were on finasteride alone (group A), while the remaining received in addition an oral contraceptive (group B). Clinical, hormonal and biochemical evaluation were performed before, and after 3 and 6 months of treatment. Clinical evaluation was repeated 6 months after drug discontinuation in seven patients. Treatment was well tolerated by all patients; no side effects or adverse reactions were reported. A significant improvement of hirsutism was obtained by finasteride; clinical score observed at the 6th month of therapy was reduced from 11.71 +/- 2.23 to 7.92 +/- 1.81 (p < 0.05) and from 14.92 +/- 6.13 to 9.3 +/- 2.75 (p < 0.05) in group A and B, respectively. Clinical score in seven patients was still 8.61 +/- 2.28 (p < 0.05) 6 months after the end of therapy. Finasteride treatment alone (group A) induced a slight increase, though not significant, in serum androgens; DHT and SHBG did not change. In group B (finasteride plus oral contraceptive) total testosterone and free testosterone showed no significant decrease; after 6 months of therapy DHT was reduced significantly, while SHBG levels were increased. These data demonstrate that 5 alpha-reductase inhibition may be an effective treatment in women suffering from idiopathic hirsutism. This approach may be attractive due to the absence of adverse reactions, although the necessity of an adequate contraception should be kept in mind.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854686     DOI: 10.1007/BF03350800

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Brief report: the molecular basis of steroid 5 alpha-reductase deficiency in a large Dominican kindred.

Authors:  A E Thigpen; D L Davis; T Gautier; J Imperato-McGinley; D W Russell
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

2.  Structure of human type II 5 alpha-reductase gene.

Authors:  F Labrie; Y Sugimoto; V Luu-The; J Simard; Y Lachance; D Bachvarov; G Leblanc; F Durocher; N Paquet
Journal:  Endocrinology       Date:  1992-09       Impact factor: 4.736

3.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

Authors:  A E Thigpen; R I Silver; J M Guileyardo; M L Casey; J D McConnell; D W Russell
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

4.  Fatal and nonfatal hepatotoxicity associated with flutamide.

Authors:  D K Wysowski; J P Freiman; J B Tourtelot; M L Horton
Journal:  Ann Intern Med       Date:  1993-06-01       Impact factor: 25.391

5.  Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.

Authors:  P Moghetti; R Castello; C M Magnani; F Tosi; C Negri; D Armanini; G Bellotti; M Muggeo
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

6.  Azasteroids as inhibitors of testosterone 5 alpha-reductase in mammalian skin.

Authors:  T N Mellin; R D Busch; G H Rasmusson
Journal:  J Steroid Biochem Mol Biol       Date:  1993-02       Impact factor: 4.292

7.  Circulating dihydrotestosterone may not reflect peripheral formation.

Authors:  V Toscano; R Horton
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

8.  Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; P Morosini; R De Pirro
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

9.  The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.

Authors:  A L Dallob; N S Sadick; W Unger; S Lipert; L A Geissler; S L Gregoire; H H Nguyen; E C Moore; W K Tanaka
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

10.  Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.

Authors:  F Fruzzetti; D de Lorenzo; D Parrini; C Ricci
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more
  2 in total

Review 1.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

2.  Hirsutism: evaluation and treatment.

Authors:  Silonie Sachdeva
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.